Abbott Anticipates Humira sBLA For Crohn’s Disease By Year-End
This article was originally published in The Pink Sheet Daily
Executive Summary
Application would be buoyed by new Phase III remission data.
You may also be interested in...
May The Schwarz Be With You: UCB Proposes $5.6 Bil. Acquisition
Existing Schwarz deal with Pfizer unaffected by merger that would create a neurology heavyweight.
May The Schwarz Be With You: UCB Proposes $5.6 Bil. Acquisition
Existing Schwarz deal with Pfizer unaffected by merger that would create a neurology heavyweight.
Crohn’s Competition Coming
Humira filing will challenge J&J’s Remicade as Crohn’s disease treatment.